The Efficacy of Mirodenafil for Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Middle-Aged Males
The World Journal of Men's Health
; : 145-150, 2014.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-106558
Responsible library:
WPRO
ABSTRACT
PURPOSE:
The aim of this study was to investigate the efficacy of mirodenafil in middle-aged male patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). MATERIALS ANDMETHODS:
Eighty-eight males with CP/CPPS were randomized to receive either levofloxacin (500 mg/d) (group L, 40 patients) or levofloxacin (500 mg/d) and mirodenafil (50 mg/d) (group ML, 48 patients) for six weeks. The International Prostate Symptom Score (IPSS), National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), and erectile function (EF) domain scores of the International Index of Erectile Function (IIEF) questionnaire were used to grade symptoms at baseline and 6 weeks after treatment.RESULTS:
The mean change in total IPSS from baseline was higher in group ML than that in group L (group L, -1.1 vs. group ML, -4.3; p<0.05). Significant improvements were also seen in the IPSS voiding subscore (group L, -0.7 vs. group ML, -3.0; p<0.05). Changes observed in the NIH-CPSI of group ML at six weeks were greater than those at baseline (group L, -3.2 vs. group ML, -7.2; p<0.05). Significant improvements were seen in the NIH-CPSI voiding (group L, -0.5 vs. group ML, -1.7; p<0.05) and quality of life domains (group L, -1.0 vs. group ML, -1.8; p<0.05). Group ML showed a significantly greater increase in the IIEF-EF score than did group ML (group L, +0.2 vs. group ML, +7.8; p<0.05).CONCLUSIONS:
Mirodenafil (50 mg once daily) was well tolerated and resulted in significant symptomatic improvement in middle-aged males with CP/CPPS.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Prostate
/
Prostatitis
/
Quality of Life
/
Surveys and Questionnaires
/
Treatment Outcome
/
Pelvic Pain
/
Phosphodiesterase 5 Inhibitors
/
Levofloxacin
/
Erectile Dysfunction
Type of study:
Controlled clinical trial
Aspects:
Patient-preference
Limits:
Humans
/
Male
Language:
English
Journal:
The World Journal of Men's Health
Year:
2014
Document type:
Article